MetaCap

Alkermes plc (ALKS)

NASDAQ: ALKSHealth CareBiotechnology: Pharmaceutical PreparationsUSD

44.94-1.24 (-2.69%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

ALKS stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$0.01
52-week range
27.00 – 55.67
Day range
44.83 – 46.89
Volume / Avg
1.08M / 1.90M
Beta
—

52-week range

$27.00$55.67

ALKS stock today

On Nov 20, ALKS ended the session at $44.94, shedding $1.24 (2.69%), versus the S&P 500's 3.70% decline. Shares are 19.3% below their 52-week high of $55.67, set on Jul 7, 2026 and 66.4% above the 52-week low of $27.00, in the middle of the past year's range. ALKS is up 60.6% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 57.1%.

Alkermes has posted a net loss over the last twelve months (EPS of -$0.01), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Alkermes

Company profile

Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Blair C. Jackson
Headquarters
Dublin
Employees
2,050
IPO year
1991

Financial highlights

Full financials

In fiscal 2025, Alkermes generated $1.48 billion in revenue, down 5.2% from fiscal 2024, its first annual decline since 2024. Net income was $241.7 million (-34.2% year over year), for a net margin of 16.4% versus a median of -4.1% in the prior 5 years. Gross margin was 86.7% (up from 84.2%) and operating margin 17.2%.

Alkermes annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$1.48B$1.56B$1.66B$1.11B$1.17B
Growth-5.25%-6.36%+49.61%-5.28%+13.00%
Net income$241.66M$367.07M$355.76M$-158.27M$-48.17M
EPS (diluted)$1.43$2.17$2.10$-0.97$-0.29

Analyst forecast

Forecast

Consensus (20 analysts)

buy

Avg. price target

$57.74+28.48%

  • Strong buy 3
  • Buy 12
  • Hold 4
  • Sell 0
  • Strong sell 1

Target range

Low $38.00High $83.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 3, 2026
EPS actual vs est.
$0.49 vs $-0.08
Surprise
+712.50%

ALKS news

All ALKS news

Alkermes peers

Health Care sector
ALKS peer companies
CompanyPrice% ChgMarket capCompare
KNSAKiniksa Pharmaceuticals International plc Class A93.90+0.38%$7.38Bvs ALKS
AMRXAmneal Pharmaceuticals Inc. Class A21.12-1.26%$7.36Bvs ALKS
RYTMRhythm Pharmaceuticals Inc.112.36-3.80%$7.79Bvs ALKS
PTGXProtagonist Therapeutics Inc.121.40-2.11%$7.92Bvs ALKS
SMMTSummit Therapeutics Inc.9.95-5.87%$7.96Bvs ALKS
CYTKCytokinetics Incorporated50.78-1.32%$7.07Bvs ALKS
CORTCorcept Therapeutics Incorporated63.62-2.09%$6.96Bvs ALKS
AXSMAxsome Therapeutics Inc.129.36-4.66%$6.80Bvs ALKS

Indexes, lists and sector

Alkermes stock FAQ

What is Alkermes's stock price today?

ALKS last traded at $44.94 as of Nov 20, 4:00 PM EST, down 2.69% on the day. Prices are delayed at least 15 minutes.

Does Alkermes pay a dividend?

No. Alkermes does not currently pay a regular cash dividend.

Who is Alkermes's CEO?

Mr. Blair C. Jackson is the chief executive officer of Alkermes plc, which has about 2,050 employees.

Has ALKS ever split its stock?

Yes. The most recent ALKS stock split was a 2-for-1 split on May 15, 2000.

What is the ALKS 52-week high?

The 52-week high for ALKS is $55.67 and the 52-week low is $27.00. The stock is currently 19.3% below its high.

Compare ALKS